Conatus Pharmaceuticals Announces Acceptance of Abstracts for EASL Meeting
- Late Breaker Oral Presentation of Phase 2 Liver Cirrhosis Trial Three-month Data - - Poster of Preclinical Data Addressing Safety of Caspase Inhibition in Cancer Treatment - SAN DIEGO, March 30, 2016 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. ( …